Piramal Pharma has successfully completed the acquisition of 1,46,400 equity shares of ₹10 each of Yapan Bio, an associate company, from existing shareholders for an aggregate cash consideration of approximately ₹76 crore. According to the latest regulatory filing, this transaction represents a significant increase in Piramal Pharma's ownership position in the biotechnology company, elevating it from an associate to a direct subsidiary relationship. The acquisition was executed through the purchase of shares from existing shareholders, demonstrating the company's commitment to increasing its strategic stake in the associate company.
Following the acquisition, Piramal Pharma's shareholding in Yapan Bio has increased substantially from 33.33% to 74.00% of the equity share capital. As reported in the regulatory filing, this represents a 40.67 percentage point increase in the pharmaceutical company's ownership stake in the biotechnology associate company, with Yapan Bio transitioning from an associate to a direct subsidiary of Piramal Pharma Limited. The move follows a prior communication on 10 August 2026, regarding the company's exercise of a call option to acquire the additional equity, reflecting a commitment to strengthening its position in biologics development and manufacturing.
The acquisition was executed through the purchase of 1,46,400 equity shares at ₹10 each, totaling approximately ₹14.64 crore. According to the regulatory filing, the transaction involved the purchase of shares from existing shareholders of Yapan Bio, demonstrating the company's commitment to increasing its strategic stake in the associate company. Piramal Pharma disclosed this transaction in a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, 2015, with the latest BSE filing further clarifying that Yapan Bio has transitioned from being an associate company to becoming a direct subsidiary.
Yapan Bio, based in Hyderabad, operates as a Contract Development and Manufacturing Organisation (CDMO) specialising in process development, characterisation, and Phase I/II GMP manufacturing services for vaccines and biologics. As per the latest financial data, Yapan Bio's revenue from operations has demonstrated notable fluctuations, with figures standing at ₹26.34 crore in fiscal year 2026, ₹54.40 crore in fiscal year 2025, and ₹26.91 crore in fiscal year 2024. The acquisition aligns with Piramal Pharma's strategy to enhance its integrated service offerings by incorporating Yapan Bio's advanced large molecule capabilities, with the promoter group now deemed to have an indirect interest in Yapan Bio through this substantial investment.
This acquisition represents a significant strategic move for Piramal Pharma, as the promoter group is indirectly interested in Yapan Bio through this substantial investment. As a direct subsidiary, Yapan Bio's contributions are anticipated to synergise with Piramal Pharma's current operations, potentially driving business growth in the biotechnology domain. The move aims to bolster the company's ability to develop and scale complex biologic therapies more efficiently, further expanding its footprint in the biologics sector. This development comes on the heels of Piramal Pharma's prior announcement on 10 August 2026, regarding its intention to exercise a call option for this acquisition, reflecting a commitment to strengthening its position in biologics development and manufacturing.
